Comparative Pharmacology
Head-to-head clinical analysis: HYDRALAZINE HYDROCHLORIDE W HYDROCHLOROTHIAZIDE 100 50 versus RENESE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HYDRALAZINE HYDROCHLORIDE W HYDROCHLOROTHIAZIDE 100 50 versus RENESE.
HYDRALAZINE HYDROCHLORIDE W/ HYDROCHLOROTHIAZIDE 100/50 vs RENESE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Hydralazine: Direct vasodilation of arterioles via unknown mechanism, possibly involving nitric oxide. Hydrochlorothiazide: Thiazide diuretic that inhibits the Na+/Cl- cotransporter in the distal convoluted tubule, increasing excretion of sodium and water.
Thiazide diuretic that inhibits the sodium-chloride symporter in the distal convoluted tubule, reducing sodium and chloride reabsorption, leading to increased diuresis and vasodilation.
1 tablet (hydralazine 100 mg / hydrochlorothiazide 50 mg) orally once daily. Maximum: 1 tablet daily. Titrate from lower doses of individual components.
Initial 2.5-5 mg orally once daily; increase by 2.5-5 mg every 2-4 weeks up to 20 mg/day as needed.
None Documented
None Documented
Hydralazine: 2-8 hours (prolonged in renal impairment); Hydrochlorothiazide: 6-15 hours (increased in renal impairment)
13–15 hours; prolonged in renal impairment (CrCl <30 mL/min: up to 30–40 hours).
Hydralazine: 90% renal metabolites, 10% feces; Hydrochlorothiazide: >95% renal (tubular secretion) as unchanged drug
Renal: ~85% unchanged; fecal: ~15% (via bile).
Category A/B
Category C
Thiazide Diuretic
Thiazide Diuretic